Search Results - "Karp, S E"

Refine Results
  1. 1

    Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer by FOULKES, W. D, WONG, N, POLLAK, M. N, BRUNET, J.-S, BEGIN, L. R, JIAN CHUN ZHANG, MARTINEZ, J. J, ROZEN, F, TONIN, P. N, NAROD, S. A, KARP, S. E

    Published in Clinical cancer research (01-12-1997)
    “…Germ-line mutations in BRCA1 confer an increased risk of developing breast and ovarian cancer, but little is known about the clinical course of breast cancer…”
    Get full text
    Journal Article
  2. 2

    Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women by Karp, Stephen E., Tonin, Patricia N., Bégin, Louis R., Martinez, John J., Zhang, Jian Chun, Pollak, Michael N., Foulkes, William D.

    Published in Cancer (01-08-1997)
    “…BACKGROUND In the Ashkenazim, three recurrent germline mutations have been identified in the breast carcinoma susceptibility genes BRCA1 and BRCA2: 185delAG,…”
    Get full text
    Journal Article
  3. 3

    Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer by Rosenberg, S A, Lotze, M T, Yang, J C, Linehan, W M, Seipp, C, Calabro, S, Karp, S E, Sherry, R M, Steinberg, S, White, D E

    Published in Journal of clinical oncology (01-12-1989)
    “…We performed an escalating dose study of the combined administration of interleukin-2 (IL-2) and alpha-interferon (alpha-IFN) in 94 patients with metastatic…”
    Get more information
    Journal Article
  4. 4

    A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor : correlation with antigen presentation capability by RESTIFO, N. P, SPIESS, P. J, KARP, S. E, MULÉ, J. J, ROSENBERG, S. A

    Published in The Journal of experimental medicine (01-06-1992)
    “…To be recognized by CD8+ T lymphocytes, target cells must process and present peptide antigens in the context of major histocompatibility complex (MHC) class I…”
    Get full text
    Journal Article
  5. 5

    Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor by Karp, SE, Farber, A, Salo, JC, Hwu, P, Jaffe, G, Asher, AL, Shiloni, E, Restifo, NP, Mule, JJ, Rosenberg, SA

    Published in The Journal of immunology (1950) (01-02-1993)
    “…Recent investigations have demonstrated that the in vivo growth of weakly immunogenic murine tumors can be inhibited by genetic manipulations that enable them…”
    Get full text
    Journal Article
  6. 6

    Evaluation of stereotactic core needle biopsy (SCNB) of the breast at a single institution by LATOSINSKY, S, CORNELL, D, BEAR, H. D, KARP, S. E, LITTLE, S, DE PAREDES, E

    Published in Breast cancer research and treatment (01-04-2000)
    “…Stereotactic core needle biopsy (SCNB) has become a popular method for diagnosis of occult breast abnormalities. There are few large series of SCNB from a…”
    Get full text
    Journal Article
  7. 7

    The Lifetime Risks of Breast Cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations by SATAGOPAN, Jaya M, OFFIT, Kenneth, FOULKES, William, ROBSON, Mark E, WACHOLDER, Sholom, ENG, Christine M, KARP, Stephen E, BEGG, Colin B

    “…Several studies using families with multiple occurrences of breast cancer have provided evidence for a very high lifetime penetrance in carriers of BRCA1 or…”
    Get full text
    Journal Article
  8. 8

    A murine model for the immunotherapy of head and neck squamous cell carcinoma by Hier, M P, Black, M J, Shenouda, G, Sadeghi, N, Karp, S E

    Published in The Laryngoscope (01-10-1995)
    “…A murine model for the immunotherapy of head and neck cancer was established. The AT-84 tumor, a spontaneously arising oral squamous cell tumor of C3H mice,…”
    Get more information
    Journal Article
  9. 9

    Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells by Katabi, M M, Chan, H L, Karp, S E, Batist, G

    Published in Human gene therapy (20-01-1999)
    “…The use of tissue- or tumor-selective promoters in targeted gene therapy for cancer depends on strong and selective activity. Hexokinase type II (HK II)…”
    Get more information
    Journal Article
  10. 10

    Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma by Sadeghi, N, Black, M J, Hier, M P, Shenouda, G, Karp, S E

    “…To study immunotherapy for advanced head and neck squamous cell carcinoma using AT-84, a spontaneously arising murine tumor. We examined the draining lymph…”
    Get more information
    Journal Article
  11. 11

    Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma by Karp, S E

    Published in Journal of immunotherapy (1997) (01-01-1998)
    “…High-dose therapy with interleukin-2 (IL-2) can produce significant responses in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Several…”
    Get more information
    Journal Article
  12. 12

    Clinical management of BRCA1- and BRCA2-associated breast cancer by Karp, Stephen E.

    Published in Seminars in surgical oncology (01-06-2000)
    “…The recent discovery of the breast cancer‐associated genes BRCA1 and BRCA2 has changed the clinical care provided to women at high risk of breast cancer. We…”
    Get full text
    Journal Article
  13. 13

    In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor by Karp, SE, Hwu, P, Farber, A, Restifo, NP, Kriegler, M, Mule, JJ, Rosenberg, SA

    Published in The Journal of immunology (1950) (15-09-1992)
    “…We have previously demonstrated that murine tumor cells transduced with a retrovirus containing the cDNA encoding wild-type human TNF regress in vivo when…”
    Get full text
    Journal Article
  14. 14

    Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma : generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor by SHILONI, E, KARP, S. E, CUSTER, M. C, SHILYANSKY, J, RESTIFO, N. P, ROSENBERG, S. A, MULE, J. J

    Published in Cancer immunology and immunotherapy (01-10-1993)
    “…Gene modification of tumor cells with the cDNA for interferon γ (IFNγ) has been shown to increase the immunogenicity of some tumor cells. In order to explore…”
    Get full text
    Journal Article
  15. 15

    super(31)P and super(2)H Relaxation Studies of Helix VII and the Cytoplasmic Helix of the Human Cannabinoid Receptors Utilizing Solid-State NMR Techniques by Tiburu, E K, Karp, E S, Birrane, G, Struppe, JO, Chu, S, Lorigan, G A, Avraham, S, Avraham, H K

    Published in Biochemistry (Easton) (13-06-2006)
    “…Cannabinoid receptors are G-protein-coupled receptors comprised of seven transmembrane helices. We hypothesized that the extended helix of the receptor…”
    Get full text
    Journal Article
  16. 16

    Solid-State NMR Spectroscopic Studies of an Integral Membrane Protein Inserted into Aligned Phospholipid Bilayer Nanotube Arrays by Lorigan, Gary A, Dave, Paresh C, Tiburu, Elvis K, Damodaran, Krishnan, Abu-Baker, Shadi, Karp, Ethan S, Gibbons, William J, Minto, Robert E

    Published in Journal of the American Chemical Society (11-08-2004)
    “…This communication demonstrates for the first time that solid-state NMR spectroscopic studies can be used to investigate aligned phospholipid bilayer nanotube…”
    Get full text
    Journal Article
  17. 17

    Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2

    Published in Human gene therapy (01-02-1992)
    “…When tumor is resected from patients as part of the natural course of their treatment, an attempt will be made to establish a tissue culture line of the tumor…”
    Get more information
    Journal Article
  18. 18

    Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer by Parviz, Maryam, Cassel, Jay Brian, Kaplan, Brian J., Karp, Stephen E., Neifeld, James P., Penberthy, Lynne T., Bear, Harry D.

    Published in Journal of surgical oncology (01-10-2003)
    “…Purpose Multiple prospective, randomized studies show that breast conservation therapy (BCT) results in survival rates equal to mastectomy (Mx) for patients…”
    Get full text
    Journal Article
  19. 19

    Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor by Shiloni, E, Karp, S E, Custer, M C, Shilyansky, J, Restifo, N P, Rosenberg, S A, Mulé, J J

    Published in Cancer immunology, immunotherapy : CII (01-10-1993)
    “…Gene modification of tumor cells with the cDNA for interferon gamma (IFN gamma) has been shown to increase the immunogenicity of some tumor cells. In order to…”
    Get full text
    Journal Article
  20. 20